Shots:

• Boston Scientific to acquire Preventice for ~$1.2B including $925M as up front- up to an additional $300M as commercial milestones. However- Boston Scientific has built up a 22% stake in Preventice- which is expected to lower up front to $720M upfront & $230 million in milestone respectively
• The acquisition is expected to be close in mid-2021. The acquisition will add external cardiac monitoring technologies and services provider to Boston Scientific and expand its rhythm management diagnostics portfolio and capabilities
• The Preventice portfolio includes the BodyGuardian family of remote- wearable cardiac monitors for adult and pediatric patients

 ­ Ref: Boston Scientific| Image: CRG